Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

NCT02598427 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Inadequate enrollment

Conditions

HER2 Positive Untreated Metastatic Breast Cancer
Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer

Interventions

DRUG: Pertuzumab
DRUG: Trastuzumab

Sponsor

Kimberly Blackwell